BIOCRYST PHARMACEUTICALS INC (BCRX) Stock
2 members of Congress disclosed 5 trades in BCRX since 2022: 4 purchases and 1 sale, most recently Gilbert Cisneros (purchase, Jul 10, 2026). 8 of the hedge funds AlphaScala tracks reported BCRX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $33.95M.
Which members of Congress traded BIOCRYST PHARMACEUTICALS INC (BCRX)?
Most recent: Gilbert Cisneros (purchase, Jul 10, 2026); records start Aug 11, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-07-10 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-13 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-10-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-09-15 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2022-08-11 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all BCRX political trades →Which hedge funds own BCRX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.39M | $33.95M | +1708% |
| Renaissance Technologies Jim Simons (founder) | 2.53M | $25.30M | +226% |
| Citadel Ken Griffin | 1.76M | $17.59M | +73% |
| Bridgewater Associates Ray Dalio | 491K | $4.91M | -23% |
| D.E. Shaw David Shaw | 409K | $4.09M | +35% |
| Point72 Steve Cohen | 261K | $2.61M | NEW |
| Marshall Wace | 253K | $2.53M | +3% |
| Hussman Investment Trust John Hussman | 210K | $2.10M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →BCRX price chart
Powered by TradingViewWhat does BIOCRYST PHARMACEUTICALS INC do?
BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, computer modeling, and medicinal chemistry, the company focuses on structure-guided drug design to create oral therapeutics for difficult-to-treat rare diseases. Its pipeline and products address critical therapeutic areas, including hereditary angioedema, acute and uncomplicated seasonal influenza, filoviruses such as Ebola and Marburg viruses, and oncology. BioCryst Pharmaceuticals Inc. operates within the healthcare sector, particularly in drug manufacturing for specialty and generic applications, contributing to treatments for rare conditions and emerging infectious threats. Founded in 1986 and headquartered in Durham, North Carolina, it plays a vital role in advancing innovative therapies for underserved patient populations in the biopharmaceutical market.